Scholarlink

Purpose <p>Peripheral neuropathy is one of the most problematic adverse effects of docetaxel. We previously reported that dexamethasone (DEX) prevents taxane-associated acute pain syndrome (T-APS) in a dose-dependent manner, which might be a partial manifestation of chemotherapy-induced peripheral neuropathy (CIPN), in breast cancer treatment. Therefore, this study examined the dose-dependent prophylactic efficacy of DEX against CIPN.</p> Methods <p>Female patients with breast cancer receiving docetaxel-containing treatments (75 mg/m<sup>2</sup>) were divided into two groups according to DEX dosage on days 2–4; an 8&#xa0;mg group (n = 56) and a 4 mg group (n = 28) and retrospectively evaluated. The primary endpoint in this study was defined as the development of grade ≥ 2 CIPN during 4 cycles of the treatment.</p> Results <p>The incidence of grade ≥ 2 CIPN was 32.1% in the 4&#xa0;mg group and 10.7% in the 8&#xa0;mg group and was significantly lower in the 8&#xa0;mg group (<i>P</i> = 0.03). The incidence of all-grade CIPN was lower in the 8&#xa0;mg group than in the control group, although the difference was not statistically significant (<i>P</i> = 0.06). Onset time of all-grade and grade ≥ 2 CIPN in the 8&#xa0;mg group was significantly delayed compared to that in the 4&#xa0;mg group (<i>P</i> = 0.003 and 0.01, respectively). Additionally, 8&#xa0;mg/day of DEX was identified as a preventive factor for all-grade CIPN, although the evaluation of grade ≥ 2 symptoms was not possible.</p> Conclusion <p>Our study found that DEX attenuated docetaxel-induced CIPN in a dose-dependent manner during real-world breast cancer treatment. Further studies are needed to develop better CIPN management strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dexamethasone dose-dependently attenuates docetaxel-induced peripheral neuropathy in breast cancer treatment

  • 期刊论文

  • 发表日期：

    2025年4月7日

查看全文
  • Ryota Kanno,
  • Yoshitaka Saito,
  • Yoh Takekuma,
  • Masato Takahashi,
  • Tomohiro Oshino,
  • Mitsuru Sugawara

摘要

Purpose

Peripheral neuropathy is one of the most problematic adverse effects of docetaxel. We previously reported that dexamethasone (DEX) prevents taxane-associated acute pain syndrome (T-APS) in a dose-dependent manner, which might be a partial manifestation of chemotherapy-induced peripheral neuropathy (CIPN), in breast cancer treatment. Therefore, this study examined the dose-dependent prophylactic efficacy of DEX against CIPN.

Methods

Female patients with breast cancer receiving docetaxel-containing treatments (75 mg/m2) were divided into two groups according to DEX dosage on days 2–4; an 8 mg group (n = 56) and a 4 mg group (n = 28) and retrospectively evaluated. The primary endpoint in this study was defined as the development of grade ≥ 2 CIPN during 4 cycles of the treatment.

Results

The incidence of grade ≥ 2 CIPN was 32.1% in the 4 mg group and 10.7% in the 8 mg group and was significantly lower in the 8 mg group (P = 0.03). The incidence of all-grade CIPN was lower in the 8 mg group than in the control group, although the difference was not statistically significant (P = 0.06). Onset time of all-grade and grade ≥ 2 CIPN in the 8 mg group was significantly delayed compared to that in the 4 mg group (P = 0.003 and 0.01, respectively). Additionally, 8 mg/day of DEX was identified as a preventive factor for all-grade CIPN, although the evaluation of grade ≥ 2 symptoms was not possible.

Conclusion

Our study found that DEX attenuated docetaxel-induced CIPN in a dose-dependent manner during real-world breast cancer treatment. Further studies are needed to develop better CIPN management strategies.